Vivalyx

Vivalyx

Private
AachenHealthcare & Life Scienceshttps://vivalyx.com

Last Round

VC Round

Feb 19, 2025

Total Funding Raised

$10.1M

Momentum Score

75 /100

Company Overview

Vivalyx is a biotech company that has developed a patented, blood-free preservation liquid called Omnisol for organ preservation before transplantation.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Clinical Trials, Advanced Materials

Business Model

B2B

Customer Profile

Hardware Sales, Government Contracts

AI Layer

Non-AI

Keywords

organ preservation solutionnormothermic machine perfusionwarm perfusionsynthetic perfusateblood-free perfusateorgan revitalizationex-vivo organ perfusionorgan perfusionorgan preservationorgan care systemorgan viability assessmentorgan procurement organizationsOPOs

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Vivalyx Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Vivalyx Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
VC RoundFeb 19, 2025
GrantFeb 19, 2025
SeedApr 30, 2024
Pre SeedJun 15, 2023

Key People

Founding team and executive leadership

Benedict Doorschodt

Chief Technology Officer Co-Founder

Founding Team

René H. Tolba

Founder And Chief Medical Officer

Founding Team

Andreas Schumacher

CEO Co-Founder

Founding Team

Vivalyx Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 1, 2026

    Hiring Head of Production for Omnisol's European launch.

  • Feb 19, 2025

    Secured $2.69M in grant funding.

Vivalyx Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Vivalyx Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Vivalyx's valuation, stock price, and market status.

Firmographic Details

HeadquartersAachen
Employee Range18
Year Founded2022
Last FundingFeb 19, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.